Regado Biosciences, a drug development company whose technology was invented at Duke University, recently raised new funding that will see it through the bulk of next year.
The company, which is developing several blood thinners, isn't saying how much money it raised. CEO David Mazzo called the new funding an extension of the $40 million round of financing it completed in December 2009.
Regado is headquartered in Basking Ridge, N.J., although roughly half of its 31 employees are based in Durham.
"I guess we call [New Jersey] the corporate headquarters because this is where I, the CEO, am based," said Mazzo. "But our CSO, our CFO and half the company's staff and all our laboratory and research is done in the Durham facility."
The company's leading experimental drug, REG1, is an anti-coagulant that is aimed for use during angioplasty procedures and stent implants. The company expects to begin the third and final phase of clinical trials required before seeking regulatory approval.
In April, Regado disclosed "very, very exciting" results from a Phase 2b trial of REG1, Mazzo said.